FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379648475> ?p ?o ?g. }

• W4379648475 endingPage "1418" @default.
• W4379648475 startingPage "1418" @default.
• W4379648475 abstract "Background Baricitinib, an orally selective inhibitor of JAK1 and JAK2, was approved for adult patients with moderate-to-severe rheumatoid arthritis (RA) in China. The recommended dose is 2mg once daily and 4mg once daily in patients who have inadequately responded to baricitinib 2mg once daily (for 3 months) or TNF inhibitors. A single-arm, prospective, non-interventional post-marketing safety study (PMSS) was conducted in Chinese RA patients to describe the safety and effectiveness of baricitinib at 24 weeks. Objectives To describe the safety and effectiveness of baricitinib in real-world setting of treating patients with moderate to severe active RA. Methods This PMSS (starting July 2020) included 667 patients with RA treated with baricitinib (2 mg or/and 4mg/day) and followed up for 24 weeks. Safety and effectiveness (disease activity) were assessed for 24 weeks. All statistical analyses are descriptive. Results Safety analyses included 667 patients (females=82.3%, mean age=53.3 years, mean RA duration 86.9 months). 106 (15.9%) were ≥65 and <75years and 19 (2.8%) were ≥75 years. 29 (4.3%) had previously received biologic therapy. Baricitinib dose regimen was as follows: 2 mg/day, n = 580 (87.0%); 4 mg/day, n = 53 (7.9%); 2/4 mg, n = 34 (5.1%). Concomitant use of MTX and leflunomide occurred in 54.3% and 35.5%, respectively. The overall exposure of baricitinib was 262.1 patient-years; 197 (29.5%) patients withdrew from the study, mostly for patient’s decision (n = 101). Adverse events (AEs) occurred in 250 (37.5%) patients [serious: 28 (4.2%)]. Two patients (0.3%) died: one of pneumonia and one with no cause reported. The incidence of serious infection, herpes zoster and hepatotoxicity was 0.6%, 1.0%, and 3.4%, respectively. No case met laboratory criteria for potential Hy’s Law (ALT/AST ≥3 x ULN and TBL ≥2 x ULN). Malignancy occurred in one patient (thyroid cancer). No venous thromboembolism (VTE) or major adverse cardiovascular event (MACE) were reported during the study observation period ( Table 1 ). In the effectiveness analysis at Week 24, the proportions of patients achieving remission/ low disease activity were 66.6% (235/353) for DAS28-CRP, 64.6% (228/353) for SDAI, and 63.5% (242/381) for CDAI ( Figure 1 ). Conclusion In conclusion, the safety and effectiveness profile of baricitinib in this Chinese PMSS was generally similar to that in the global RA population with no VTEs or MACE reported and no new safety signals. References NIL. Table 1. Safety summary among patients with RA treated with baricitinib n (%) PYE [EAIR] Safety Population (N=667) 12 weeks 24 weeks AE 214 (32.08) 124.04 [172.52] 250 (37.48) 198.58 [125.89] AEs related to study treatment as judged by the investigator 95 (14.24) 139.99 [67.86] 120 (17.99) 236.65 [50.71] Death / 2 (0.30) 261.30 [0.77] SAE 22 (3.30) 147.03 [14.96] 28 (4.20) 256.72 [10.91] SAEs related to study treatment as judged by the investigator 8 (1.20) 148.32 [5.39] 10 (1.50) 260.30 [3.84] Treatment discontinuation due to AEs 20 (3.00) 148.18 [13.50] 24 (3.60) 260.79 [9.20] AESI Serious infection 3 (0.45) 148.52 [2.02] 4 (0.60) 260.99 [1.53] Hepatotoxicity 16 (2.40) 147.13 [10.87] 23 (3.45) 256.76 [8.96] VTE 0 148.63 [0.00] 0 261.30 [0.00] Herpes zoster, n (% ) 3 (0.45) 7 (1.05) Malignancy, n (%) 1 (0.15) 1 (0.15) MACE, n (%) 0 0 Abbreviations: AE= adverse event; AESI= adverse event with special interest; EAIR= exposure-adjusted incidence rate; MACE= major adverse cardiovascular events; N= number of patients in the safety analysis set; n= number of patients in the specified category; PYE= patient-years of exposure; RA= rheumatoid arthritis; SAE= serious adverse event; VTE= venous thromboembolism Used EAIR per 100 PYE (patient exposure censored at the event). AESI was based on the judgement of investigator recorded in eCRF (electronic case report form) MACE included myocardial infarction, cardiovascular death, and stroke. Acknowledgements: NIL. Disclosure of Interests Chan-yuan Wu: None declared, Qian Wang: None declared, Jian Shi: None declared, XIUYING ZHANG: None declared, Rong Du: None declared, Jieruo Gu: None declared, Qi-huan Liu: None declared, Jiao Yu Employee of: Eli Lilly and Company, Jia-wei Xu Employee of: Eli Lilly and Company, Yan-jie Zhang Employee of: Eli Lilly and Company, Hao Zhu Employee of: Eli Lilly and Company, Mengtao Li: None declared, Xiaofeng Zeng: None declared." @default.
• W4379648475 created "2023-06-08" @default.
• W4379648475 creator A5015195367 @default.
• W4379648475 creator A5017941291 @default.
• W4379648475 creator A5028620248 @default.
• W4379648475 creator A5030035495 @default.
• W4379648475 creator A5031804038 @default.
• W4379648475 creator A5035088841 @default.
• W4379648475 creator A5040192354 @default.
• W4379648475 creator A5046175512 @default.
• W4379648475 creator A5062015729 @default.
• W4379648475 creator A5062572006 @default.
• W4379648475 creator A5067811912 @default.
• W4379648475 creator A5073523669 @default.
• W4379648475 creator A5075250916 @default.
• W4379648475 date "2023-05-30" @default.
• W4379648475 modified "2023-10-16" @default.
• W4379648475 title "AB0455 BARICITINIB IN THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN CHINA: 24-WEEK RESULTS OF POST-MARKETING SAFETY STUDY" @default.
• W4379648475 doi "https://doi.org/10.1136/annrheumdis-2023-eular.2148" @default.
• W4379648475 hasPublicationYear "2023" @default.
• W4379648475 type Work @default.
• W4379648475 citedByCount "0" @default.
• W4379648475 crossrefType "journal-article" @default.
• W4379648475 hasAuthorship W4379648475A5015195367 @default.
• W4379648475 hasAuthorship W4379648475A5017941291 @default.
• W4379648475 hasAuthorship W4379648475A5028620248 @default.
• W4379648475 hasAuthorship W4379648475A5030035495 @default.
• W4379648475 hasAuthorship W4379648475A5031804038 @default.
• W4379648475 hasAuthorship W4379648475A5035088841 @default.
• W4379648475 hasAuthorship W4379648475A5040192354 @default.
• W4379648475 hasAuthorship W4379648475A5046175512 @default.
• W4379648475 hasAuthorship W4379648475A5062015729 @default.
• W4379648475 hasAuthorship W4379648475A5062572006 @default.
• W4379648475 hasAuthorship W4379648475A5067811912 @default.
• W4379648475 hasAuthorship W4379648475A5073523669 @default.
• W4379648475 hasAuthorship W4379648475A5075250916 @default.
• W4379648475 hasBestOaLocation W43796484751 @default.
• W4379648475 hasConcept C126322002 @default.
• W4379648475 hasConcept C141071460 @default.
• W4379648475 hasConcept C188816634 @default.
• W4379648475 hasConcept C197934379 @default.
• W4379648475 hasConcept C2775905006 @default.
• W4379648475 hasConcept C2777575956 @default.
• W4379648475 hasConcept C2779384505 @default.
• W4379648475 hasConcept C2781413609 @default.
• W4379648475 hasConcept C71924100 @default.
• W4379648475 hasConceptScore W4379648475C126322002 @default.
• W4379648475 hasConceptScore W4379648475C141071460 @default.
• W4379648475 hasConceptScore W4379648475C188816634 @default.
• W4379648475 hasConceptScore W4379648475C197934379 @default.
• W4379648475 hasConceptScore W4379648475C2775905006 @default.
• W4379648475 hasConceptScore W4379648475C2777575956 @default.
• W4379648475 hasConceptScore W4379648475C2779384505 @default.
• W4379648475 hasConceptScore W4379648475C2781413609 @default.
• W4379648475 hasConceptScore W4379648475C71924100 @default.
• W4379648475 hasIssue "Suppl 1" @default.
• W4379648475 hasLocation W43796484751 @default.
• W4379648475 hasOpenAccess W4379648475 @default.
• W4379648475 hasPrimaryLocation W43796484751 @default.
• W4379648475 hasRelatedWork W1971595431 @default.
• W4379648475 hasRelatedWork W2077334362 @default.
• W4379648475 hasRelatedWork W2352294526 @default.
• W4379648475 hasRelatedWork W2365087555 @default.
• W4379648475 hasRelatedWork W2383667669 @default.
• W4379648475 hasRelatedWork W2385808951 @default.
• W4379648475 hasRelatedWork W2980569395 @default.
• W4379648475 hasRelatedWork W3030711132 @default.
• W4379648475 hasRelatedWork W4237296117 @default.
• W4379648475 hasRelatedWork W3025091143 @default.
• W4379648475 hasVolume "82" @default.
• W4379648475 isParatext "false" @default.
• W4379648475 isRetracted "false" @default.
• W4379648475 workType "article" @default.